JadeBio

Executive Summary

JadeBio is a private proteomics services company based in San Diego, specializing in mass spectrometry-based analysis. Founded in 2008, the company has developed proprietary sample preparation methods for a wide range of biological materials, including cells, tissues, biofluids, and environmental samples. Its platforms enable deep proteome coverage and detection of post-translational modifications such as phosphorylation and acetylation, as well as relative and absolute protein quantitation. JadeBio serves the growing demand for proteomic insights in drug development, biomarker discovery, and basic research, leveraging AI and machine learning capabilities to enhance data analysis. Despite its niche focus, the company remains relatively under the radar with limited public information on funding or valuation. In the competitive proteomics landscape, JadeBio differentiates through its broad sample compatibility and focus on deep coverage. However, the lack of disclosed financials or major partnerships suggests a early-to-mid stage trajectory. The company's conviction score is moderate, reflecting its specialized expertise but also uncertainties around scalability and market penetration. Key upcoming catalysts could include strategic collaborations with biopharma firms, expansion of its service offerings into clinical diagnostics, or a potential funding round to accelerate growth. Success in these areas would strengthen its position in the precision medicine ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Pharmaceutical Company40% success
• Q4 2026Launch of Enhanced Proteomics Platform30% success